we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
Company profile
Ticker
BBIO
Exchange
Website
CEO
Neil Kumar
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BridgeBio Pharma LLC
SEC CIK
Corporate docs
Subsidiaries
BB Square Capital Investors I, LP • BB Square Capital, LLC • BB Square Holdings, LLC • BB Square Investors GP I, LLC • BB Square LP • BridgeBio Chemistry, Inc. • BridgeBio Gene Therapy LLC • BridgeBio Gene Therapy Research, Inc. • BridgeBio Pharma LLC • BridgeBio Services Inc. ...
BBIO stock data
Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
6 Mar 24
8-K
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
6 Mar 24
424B5
Prospectus supplement for primary offering
4 Mar 24
8-K
Entry into a Material Definitive Agreement
4 Mar 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
22 Feb 24
8-K
Entry into a Material Definitive Agreement
18 Jan 24
8-K
Other Events
8 Jan 24
S-8
Registration of securities for employees
5 Jan 24
S-3ASR
Automatic shelf registration
2 Nov 23
Latest ownership filings
4
Neil Kumar
14 Mar 24
4
BRIAN C STEPHENSON
14 Mar 24
4
Randal W. Scott
5 Mar 24
4
BRIAN C STEPHENSON
21 Feb 24
4
CHARLES J HOMCY
21 Feb 24
4
Neil Kumar
21 Feb 24
4
Hannah Valantine
20 Feb 24
SC 13G/A
Kumar Neil
16 Feb 24
144
Notice of proposed sale of securities
15 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 524.14 mm | 524.14 mm | 524.14 mm | 524.14 mm | 524.14 mm | 524.14 mm |
Cash burn (monthly) | (no burn) | (no burn) | 52.56 mm | 46.60 mm | 48.41 mm | 41.35 mm |
Cash used (since last report) | n/a | n/a | 314.53 mm | 278.84 mm | 289.67 mm | 247.40 mm |
Cash remaining | n/a | n/a | 209.61 mm | 245.30 mm | 234.47 mm | 276.74 mm |
Runway (months of cash) | n/a | n/a | 4.0 | 5.3 | 4.8 | 6.7 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 223 |
Opened positions | 49 |
Closed positions | 34 |
Increased positions | 66 |
Reduced positions | 74 |
13F shares | Current |
---|---|
Total value | 4.21 tn |
Total shares | 195.03 mm |
Total puts | 1.63 mm |
Total calls | 2.01 mm |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
KKR Genetic Disorder | 34.51 mm | $1.37 bn |
Kohlberg Kravis Roberts & Co. | 31.06 mm | $819.08 bn |
Viking Global Investors | 25.12 mm | $662.44 bn |
Vanguard | 11.28 mm | $297.35 bn |
BLK Blackrock | 9.25 mm | $243.92 bn |
Aisling Capital Management | 6.07 mm | $160.02 bn |
Laurion Capital Management | 5.65 mm | $149.02 bn |
STT State Street | 5.04 mm | $132.92 bn |
Cormorant Asset Management | 4.66 mm | $122.95 bn |
Hillhouse Capital Advisors | 2.78 mm | $73.38 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Mar 24 | Kumar Neil | RSU Common Stock | Grant | Acquire A | No | No | 0 | 313,588 | 0.00 | 313,588 |
12 Mar 24 | Kumar Neil | Stock Option Common Stock | Grant | Acquire A | No | No | 28.7 | 45,140 | 1.30 mm | 45,140 |
12 Mar 24 | Brian C Stephenson | RSU Common Stock | Grant | Acquire A | No | No | 0 | 107,278 | 0.00 | 107,278 |
12 Mar 24 | Brian C Stephenson | Stock Option Common Stock | Grant | Acquire A | No | No | 28.7 | 15,442 | 443.19 k | 15,442 |
1 Mar 24 | Scott Randal W | Common Stock | Sell | Dispose S | Yes | Yes | 34 | 2,500 | 85.00 k | 6,500 |
16 Jan 24 | Hannah Valantine | Common Stock | Sell | Dispose S | No | Yes | 37.97 | 2,915 | 110.68 k | 1,764 |
16 Jan 24 | Hannah Valantine | Common Stock | Option exercise | Acquire M | No | Yes | 8.45 | 2,915 | 24.63 k | 4,679 |
16 Jan 24 | Hannah Valantine | Stock Option Common Stock | Option exercise | Dispose M | No | No | 8.45 | 2,915 | 24.63 k | 96,176 |
26 Dec 23 | Mccormick Frank | Common Stock | Sell | Dispose S | Yes | Yes | 42.06 | 100,000 | 4.21 mm | 627,689 |
News
Cantor Fitzgerald Maintains Overweight on BridgeBio Pharma, Raises Price Target to $70
19 Mar 24
Cantor Fitzgerald Maintains Overweight on BridgeBio Pharma, Raises Price Target to $60
11 Mar 24
BridgeBio Pharma Prices Public Offering Of 8,620,690 Common Shares At $29/Share
6 Mar 24
Mizuho Maintains Buy on BridgeBio Pharma, Lowers Price Target to $53
5 Mar 24
What's Going On With BridgeBio Pharma Stock On Monday?
4 Mar 24
Press releases
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
20 Mar 24
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
5 Mar 24
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
4 Mar 24
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
4 Mar 24
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
22 Feb 24